Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allergan brings quite a bit to the table for AbbVie. But is it enough to make the big pharma stock a smart pick right now?

Is AbbVie a Buy Now That the Allergan Deal Is Done?

AbbVie (NYSE: ABBV) shares are trading higher on Monday. Morgan Stanley analysts reinstated coverage on AbbVie with an Overweight rating and $95 price target, saying they view Humira erosion fears as "overly discounted" and that they see a "positive risk-reward skew" given the company's dividend yield.

Why AbbVie's Stock Is Trading Higher Today

Bristol-Myers

Cardinal Health

CVS Health

Walgreens

These five healthcare stocks have low P/E ratios and ample yields, making them cheap and profitable options for investors.

5 Healthcare Stocks That Are Profitable but Also Cheap

Amgen

Gilead Sciences

Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development.

Biotech Stock Rally Is Crushing Short Sellers

Allergan

AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?

AbbVie Wraps Its $63 Billion Allergan Buyout — Is AbbVie Stock A Buy?

Netflix

PayPal

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Zoetis

With "Mad Money" host Jim Cramer's "Covid-19 Index" up more than 7% in a week, two traders pick the stocks they would bet on in the group.

Jim Cramer's 'Covid-19 Index' climbs 7% in a week — here are traders' top picks in the group

The pharma giant is thriving amid the COVID-19 outbreak, but is now a good time to buy?

AbbVie Stock: Love It or Leave It?

Adverum Biotechnologies

Heron Therapeutics

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

3 Best Healthcare Stocks to Buy in May

Allergan PLC AGN, +0.01% said late Friday that AbbVie Inc. ABBV, -0.30% has closed its acquisition of the company.

AbbVie closes acquisition of Allergan

AbbVie: Redeploy The Allergan Cash

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - May 08, 2020

Johnson & Johnson

NextEra Energy

These dividend stocks are built to last years and pay out regularly to boost your retirement income.

3 Dividend Stocks  Perfect for Retirees

With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.

AbbVie's Pending Acquisition of Allergan Earns FTC Approval

Grifols, S.A.

Jazz Pharmaceuticals

Merck

Novo Nordisk

Sanofi

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market

The deal for AbbVie Inc. ABBV, +4.28% to buy Allergan Plc. AGN, +2.16% has cleared an antitrust hurdle, the companies said late Tuesday.

Abbvie's deal for Allergan clears U.S. antitrust hurdle

Abbott Labs

Activision Blizzard

Chegg

Shopify

Activision Blizzard, Shopify, Chegg, Abbott Labs and AbbVie were our top stock trades for Wednesday. That said, here's a look at the charts.

5 Top Stock Trades for Wednesday: ATVI, SHOP, CHGG, ABT, ABBV

Surprise: None of them is connected to the COVID-19 pandemic.

The 3 Most Important Things to Know About AbbVie's Q1 Update

On March 1 before the market opened, Illinois-based biopharmaceutical giant AbbVie Inc.

AbbVie Beats 1st-Quarter Estimates, Keeps 2020 Guidance

AbbVie (ABBV) earnings for the biopharmaceutical company's first quarter of 2020 have ABBV stock on the move Friday after beating estimates.
The post AbbVie Earnings: 5 Things for ABBV Stock Investors to Know About Q1 appeared first on InvestorPlace.

AbbVie Earnings: 5 Things for ABBV Stock Investors to Know About Q1

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q1 2020 Results - Earnings Call Transcript

The drugmaker also posted strong sales for its blood cancer and new immunology treatments.

AbbVie Beats Q1 Estimates as U.S. Humira Sales Rise 13.7%

AbbVie (ABBV) beats on earnings and revenues in the first quarter of 2020. Shares up in pre-market trading.

AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates

Clorox

Exxon Mobil

Where we find our good news this hour is in quarterly earnings season, where these five big-name companies all outperformed expectations.

Quarterly Earnings Beats for Exxon, Clorox, AbbVie & More

AbbVie (ABBV) delivered earnings and revenue surprises of 6.61% and 2.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Tops Q1 Earnings and Revenue Estimates

Shares of AbbVie (NYSE:ABBV) rose 1% in pre-market trading after the company reported Q1 results.

News for AbbVie Stock (ABBV)